

CONFERENCE PROGRAM AND SCHEDULE

Sunday, September 25, 2016

8:00 a.m.-8:10 a.m.

Welcome

Sheraton, Metropolitan Ballroom

Margaret Foti, American Association for Cancer Research, Philadelphia, PA

Jill O'Donnell-Tormey, Cancer Research Institute, New York, NY

8:10 a.m.-8:50 a.m.

Keynote Address

Sheraton, Metropolitan Ballroom

Engineering T cell responses to tumors: "Taking the immune system where no responses have gone before"

Philip D. Greenberg, University of Washington School of Medicine and Fred Hutchinson Cancer Research Center, Seattle, WA

8:50 a.m.-12:00 p.m.

Plenary Session 1: Antigenes and Vaccines

Sheraton, Metropolitan Ballroom

Session Chairpersons: Cornelis J. M. Melief, Leiden University Medical Center and ISA Pharmaceuticals BV, Leiden, The Netherlands and Robert D. Schreiber, Washington University School of Medicine, St. Louis, MO

8:50 a.m. Selection of cancer antigens and conditions for success of immunotherapy of cancer involving vaccination

Cornelis J. M. Melief

9:25 a.m. Therapeutically-active neoantigen-specific cancer vaccines

Robert D. Schreiber

10:00 a.m. Break

10:30 a.m. A personalized neoantigen vaccine in patients with high risk melanoma*

Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA

10:45 a.m. Individualizing cancer medicine by engineered RNA immunotherapies

Ugur Sahin, TRON, Mainz, Germany
(Not designated for CME)

11:15 a.m. T cell responses to peptide-epitopes of choice can be boosted by immune complexes of circulating anti-tetanus toxoid antibodies*

Sara Mangsbo, Uppsala University, Uppsala, Sweden

11:30 a.m. T cell recognition and tumor resistance in human cancer

Ton Schumacher, The Netherlands Cancer Institute, Amsterdam, The Netherlands

12:00 p.m.-1:30 p.m.

Lunch

Sheraton, Central Park East and West, Lennox Ballroom, Empire Ballroom (Second Floor) and New York Ballroom (Third Floor)

1:30 p.m.-4:40 p.m.

Session 2: New Checkpoints

Sheraton, Metropolitan Ballroom

Session Chairpersons: Dario A. Vignali, University of Pittsburgh, Pittsburgh, PA, and E. John Wherry, University of Pennsylvania, Philadelphia, PA

1:30 p.m. Targeting T regs in tumors

Dario A. Vignali

2:10 p.m. Molecular basis of T cell exhaustion: Insights for immunotherapy

E. John Wherry

2:40 p.m. HVEM (TNFRSF14) tumor suppressor in immune therapies of follicular lymphoma*

Darin Salloum, Memorial Sloan Kettering Cancer Center, New York, NY

*Proffered presentation

- 2:55 p.m. Break**
- 3:25 p.m. Antitumor T cells: You are what you eat**
Susan Kaech, Yale University School of Medicine, New Haven, CT
- 3:55 p.m. Identifying and overcoming metabolic checkpoints to antitumor immunity**
Greg M. Delgoffe, University of Pittsburgh Cancer Institute, Pittsburgh, PA
- 4:25 p.m. CPI-444: A potent and selective inhibitor of A2AR induces antitumor responses alone and in combination with anti-PD-L1 in preclinical and clinical studies***
Stephen Willingham, Corvus Pharmaceuticals, Burlingame, CA

5:00 p.m.-7:30 p.m. Reception and Poster Session A and Exhibits

Hilton, Americas Halls I and II
A001-A075, Americas Hall I
A075-A148, Americas Hall II

The following topics will be presented:

- Antigens and Vaccines**
- Microbiota**
- New Checkpoints**
- Tumor Microenvironment**
- Other Topics**

Monday, September 26, 2016

8:00 a.m.-8:40 a.m. William B. Coley Lecture
Sheraton, Metropolitan Ballroom

The commensal microbiota as instructors and arbiters of homeostatic and pathogenic immune responses
Dan R. Littman, NYU School of Medicine, New York, NY

8:40 a.m.-12:20 p.m. Session 3: Tumor Microenvironment

Sheraton, Metropolitan Ballroom

Session Chairpersons: Wolf Hervé Fridman, Cordeliers Research Center (INSERM), Paris, France, and Shannon J. Turley, Genentech, Inc., South San Francisco, CA

- 8:40 a.m. Tumor microenvironments: Prognostic and theranostic impacts**
Wolf Hervé Fridman
- 9:20 a.m. Emerging insights into stromal cell function in immune homeostasis and inflammation**
Shannon J. Turley
- 9:50 a.m. Targeting regulatory T cells for cancer immunotherapy**
Shimon Sakaguchi, Osaka University, Osaka, Japan
- 10:20 a.m. Break**
- 10:50 a.m. Immune suppressive and immune stimulating monocytes in cancer**
Vincenzo Bronte, University of Verona, Verona, Italy
- 11:20 a.m. Peripheral blood immune profiling of anti-PD-1 therapy in human melanoma reveals a link between T cell re-invigoration and tumor burden that predicts response***
Alexander Huang, University of Pennsylvania, Philadelphia, PA
- 11:35 a.m. Overcoming intratumor T-cell exclusion by modulation of lactate metabolism to improve immune checkpoint therapies in aggressive breast cancer***
Taha Merghoub, Memorial Sloan Kettering Cancer Center, New York, NY
- 11:50 a.m. Targeting focal adhesion kinase to awaken responses to immunotherapy in pancreatic cancer**
David G. DeNardo, Washington University School of Medicine, St. Louis, MO

*Proffered presentation

CONFERENCE PROGRAM AND SCHEDULE

12:20 p.m.-1:50 p.m.

Lunch

Sheraton, Central Park East and West, Lennox Ballroom, Empire Ballroom (Second Floor) and New York Ballroom (Third Floor)

1:50 p.m.-4:55 p.m.

Session 4: Microbiota

Sheraton, Metropolitan Ballroom

Session Chairpersons: Guido Kroemer, Gustave Roussy, Paris Decartes University, INSERM, AP-HP, Paris, France, and Giorgio Trinchieri, National Cancer Institute, Bethesda, MD

1:50 p.m. **Microbiota and cancer immunosurveillance:**

An introduction

Guido Kroemer

2:10 p.m. **Cancer as a disease of the symbiont/ metaorganism**

Giorgio Trinchieri

2:40 p.m. **Gut microbiota controls immune responses during cancer therapy**

Laurence Zitvogel, Institut Gustave Roussy, Villejuif, France

3:10 p.m. **Break**

3:40 p.m. **Bioorthogonal chemical labeling of specific immunomodulatory surface molecules in live commensals***

Jason Hudak, Harvard Medical School, Boston, MA

3:55 p.m. **Gut microbiota-host immunomodulatory interactions**

Naama Geva-Zatorsky, Harvard Medical School, Boston, MA

4:25 p.m. **Myeloid cells contribution to tumor development and response to treatment**

Miriam Merad, Icahn School of Medicine at Mount Sinai, New York, NY

5:15 p.m.-7:45 p.m.

Reception and Poster Session B and Exhibits

Hilton, Americas Halls I and II

B001-B072, Americas Hall I

B073-B145, Americas Hall II

The following topics will be presented:

Clinical Trials of Cancer Immunotherapies

Emerging Technologies

Mechanistic Merging of Treatment Modalities

New Agents and Their Mode of Action in Animals and Humans

Non-Checkpoint Immunotherapies

Trials in Progress

Other Topics

Tuesday, September 27, 2016

8:00 a.m.-11:40 a.m.

Session 5: Mechanistic Merging of Treatment Modalities

Sheraton, Metropolitan Ballroom

Session Chairpersons: Ira Mellman, Genentech, Inc., South San Francisco, CA, and Drew M. Pardoll, Johns Hopkins Medicine, Baltimore, MD

8:00 a.m. **Mechanism-based combination strategies in cancer immunotherapy**

Ira Mellman

8:40 a.m. **How much cancer can we cure with the immune system?**

Drew M. Pardoll

9:10 a.m. **Rational combinations of targeted and immunotherapies**

Patrick Hwu, The University of Texas MD Anderson Cancer Center, Houston, TX

9:40 a.m. **Break**

*Proffered presentation

10:10 a.m. Is the right flavor of inflammation the key to successful therapy?

Romina Goldszmid, National Cancer Institute, NIH, Bethesda, MD

10:40 a.m. Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab) in patients with glioblastoma (GBM): Results for cohort B (durvalumab monotherapy), bevacizumab-naïve patients with recurrent GBM

David A. Reardon, Dana-Farber Cancer Institute, Boston, MA

11:10 a.m. Identifying the epigenetic code of tumor-specific CD8 T cell dysfunction and therapeutic reprogramming*

Mary Philip, Memorial Sloan Kettering Cancer Center, New York, NY

11:25 a.m. Antitumor activity and immune correlates of PEGylated human IL-10 (AM0010) alone or in combination with anti-PD-1*

Martin Oft, ARMO, Palo Alto, CA

**11:40 a.m.-1:10 p.m.
Lunch**

Sherton, Central Park East and West, Lennox Ballroom, Empire Ballroom (Second Floor) and New York Ballroom (Third Floor)

**1:10 p.m.-5:00 p.m.
Session 6: Non-Checkpoint Immunotherapies**

Sheraton, Metropolitan Ballroom

Session Chairpersons: Glenn Dranoff, Novartis Institutes for BioMedical Research, Cambridge, MA, and Axel Hoos, GlaxoSmithKline Pharmaceuticals, Collegeville, PA

1:10 p.m. Introduction
Axel Hoos

1:30 p.m. Immune mobilizing TCR therapies against cancer (ImmTAC): A novel class of antigen specific tumor immunotherapy (Not designated for CME)

Christina M. Coughlin, Immunocore Limited, Philadelphia, PA

2:00 p.m. Targeting inducible T cell co-stimulator (ICOS) promotes effector T cell function and anti-tumor response

Patrick A. Mayes, GlaxoSmithKline Pharmaceuticals, Collegeville, PA

2:30 p.m. Small-molecule inhibitors of CD73 promote activation of human CD8+ T cells and have profound effects on tumor growth and immune parameters in experimental tumors*

Juan C. Jaen, Arcus Biosciences, Inc., Hayward, CA

2:45 p.m. Break

3:15 p.m. Microenvironmental regulation of anti-tumor immune responses: A lesson from fibroblastic cells

Viviana Cremasco, Novartis Institutes for BioMedical Research, Cambridge, MA

3:45 p.m. Macrophage repolarization therapy in metastatic colorectal cancer: CCR5 inhibition*

Niels Halama, National Center for Tumor Diseases, Heidelberg, Germany

4:00 p.m. New frontiers in oncolytic virus therapy (Not designated for CME)

David M. Reese, Amgen, Thousand Oaks, CA

4:30 p.m. Synergistic innate and adaptive integrin-targeted immunotherapy

K. Dane Wittrup, Massachusetts Institute of Technology, Cambridge, MA

*Proffered presentation

CONFERENCE PROGRAM AND SCHEDULE

Wednesday, September 28, 2016

8:00 a.m.-10:40 a.m.

Session 7: New Agents and Their Mode of Action in Animals and Humans

Sheraton, Metropolitan Ballroom

Session Chairpersons: Elizabeth M. Jaffee, Johns Hopkins Medicine, Baltimore, MD and Mark J. Smyth, QIMR Berghofer Institute, Melbourne, Australia

8:00 a.m. Combinatorial immunotherapies with the potential to reverse the carcinogenesis process

Elizabeth M. Jaffee

8:30 a.m. Novel natural killer cell targets for cancer immunotherapy

Mark J. Smyth

9:00 a.m. Targeting FSTL1 augments therapeutic activities of immune checkpoint inhibitors*

Chie Kudo-Saito, National Cancer Center, Tokyo, Japan

9:15 a.m. The anti-CD47 antibody Hu5F9-G4 is a novel immune checkpoint inhibitor with synergistic efficacy in combination with clinically active cancer targeting antibodies*

Mark P. Chao, Forty Seven, Inc, Palo Alto, CA

9:30 a.m. Cancer epigenetic and metabolic mechanisms controlling immunotherapy and chemotherapy

Weiping Zou, University of Michigan School of Medicine, Ann Arbor, MI

10:00 a.m. Manipulating inflammation to raise cancer immunogenicity

Santiago Zelenay, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom

10:30 a.m. Break

11:00 a.m.-1:10 p.m.

Session 8: Emerging Technologies

Sheraton, Metropolitan Ballroom

Session Chairperson: Matthew F. Krummel, University of California, San Francisco, CA

11:00 a.m. Visualizing tumor immune interaction in real time

Matthew F. Krummel

11:40 a.m. Technologies for personalizing cancer immunotherapies

James R. Heath, California Institute of Technology, Pasadena, CA

12:10 p.m. Tumor neoepitope selection for biomarker discovery and therapeutic vaccination

Jeffrey E. Hammerbacher, Icahn School of Medicine at Mount Sinai, New York, NY

12:40 p.m. Automatic identification of cell niches and immune interactions important for clinical outcomes using multiparameter imaging and deep neural networks*

Salil S. Bhate, Stanford University, Stanford, CA

12:55 p.m. Engineering phagocytic signaling *

Adam Williamson, University of California, San Francisco, CA

1:10 p.m.-1:20 p.m.

Closing Remarks

Axel Hoos, GlaxoSmithKline Pharmaceuticals, Collegeville, PA

1:20 p.m.

Meeting Ends

*Proffered presentation